- Home
- LGCL vs PEPG Comparison
LGCL vs PEPG Comparison
Compare LGCL & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- PEPG
- Stock Information
- Founded
- LGCL 2009
- PEPG 2018
- Country
- LGCL China
- PEPG United States
- Employees
- LGCL N/A
- PEPG N/A
- Industry
- LGCL
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- PEPG Health Care
- Exchange
- LGCL NYSE
- PEPG Nasdaq
- Market Cap
- LGCL 47.7M
- PEPG 52.4M
- IPO Year
- LGCL 2024
- PEPG 2022
- Fundamental
- Price
- LGCL $1.07
- PEPG $1.40
- Analyst Decision
- LGCL
- PEPG Buy
- Analyst Count
- LGCL 0
- PEPG 3
- Target Price
- LGCL N/A
- PEPG $7.67
- AVG Volume (30 Days)
- LGCL 277.5K
- PEPG 158.0K
- Earning Date
- LGCL 01-01-0001
- PEPG 08-07-2025
- Dividend Yield
- LGCL N/A
- PEPG N/A
- EPS Growth
- LGCL N/A
- PEPG N/A
- EPS
- LGCL 0.07
- PEPG N/A
- Revenue
- LGCL $145,690,427.00
- PEPG N/A
- Revenue This Year
- LGCL N/A
- PEPG N/A
- Revenue Next Year
- LGCL N/A
- PEPG N/A
- P/E Ratio
- LGCL $9.92
- PEPG N/A
- Revenue Growth
- LGCL N/A
- PEPG N/A
- 52 Week Low
- LGCL $0.28
- PEPG $0.88
- 52 Week High
- LGCL $3.31
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- PEPG 48.28
- Support Level
- LGCL N/A
- PEPG $1.37
- Resistance Level
- LGCL N/A
- PEPG $1.49
- Average True Range (ATR)
- LGCL 0.00
- PEPG 0.09
- MACD
- LGCL 0.00
- PEPG -0.00
- Stochastic Oscillator
- LGCL 0.00
- PEPG 38.46
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.